Updated on 2025/04/05

写真a

 
FUJISAWA Masayoshi
 
Organization
Faculty of Medicine, Dentistry and Pharmaceutical Sciences Assistant Professor
Position
Assistant Professor
External link

Degree

  • 医学博士 ( 2003.9   岡山大学 )

Research Interests

  • blood vessel invasion

  • immunohistochemistry

  • breast cancer

  • cancer microenvironment

Research Areas

  • Life Science / Human pathology  / Diagnostic pathology

 

Papers

  • Expression of SPRED2 in the lung adenocarcinoma. International journal

    Yoko Ota, Tong Gao, Masayoshi Fujisawa, I Wayan Sumardika, Masakiyo Sakaguchi, Shinichi Toyooka, Teizo Yoshimura, Akihiro Matsukawa

    Pathology, research and practice   265   155721 - 155721   2024.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    SPRED2 (Sprouty-related, EVH1 domain-containing protein 2), a negative regulator of the ERK1/2 pathway, is downregulated in several cancers; however, the significance of SPRED2 expression in lung adenocarcinoma (LUAD) remains unclear. Here, we investigated the pathological expression of SPRED2 and its relationship with ERK1/2 activation (ERK1/2 phosphorylation), Ki67 index and clinicopathological features in 77 LUAD tissues from clinical patients. Immunohistochemically, SPRED2 expression was decreased in invasive adenocarcinoma (IA) compared to adenocarcinoma in situ (AIS). There was a negative correlation between SPRED2 expression and pERK1/2 levels and a positive correlation between SPRED2 expression and Ki67 index. In the database analysis, the survival probability was higher in patients with higher SPRED2 expression than in those with lower expression. In vitro, SPRED2 deletion increased cell proliferation, migration and invasion of three LUAD cell lines (A549:KRAS mutation, H1993:METamplification, and HCC4006:EGFR mutation), whereas SPRED2 overexpression decreased these responses. Thus, SPRED2 appears to be a regulator of LUAD progression and a potential target for the treatment of LUAD.

    DOI: 10.1016/j.prp.2024.155721

    PubMed

    researchmap

  • AIを用いた組織圧切片厚の推定法の開発とAI病理診断への応用

    大原 利章, 樋口 拓浩, 藤澤 真義, 松川 昭博

    日本癌治療学会学術集会抄録集   62回   O75 - 2   2024.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    researchmap

  • HIF-PHD阻害薬による偽性低酸素はMSS大腸癌の充腫瘍免疫応答を増強する(Pseudohypoxia by HIF-PHD inhibitors activates tumor immune response for MSS colorectal cancer)

    大原 利章, 陳 悦華, 濱田 祐輔, 賀島 肇, 菊地 覚次, 野間 和広, 田澤 大, 藤澤 真義, 藤原 俊義, 松川 昭博

    日本癌学会総会記事   83回   E - 2017   2024.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • Exosomal delivery of miR-200b-3p suppresses the growth of hepatocellular carcinoma cells by targeting ERG- and VEGF-mediated angiogenesis. International journal

    Yuze Wang, Aye Moh-Moh-Aung, Tianyi Wang, Masayoshi Fujisawa, Toshiaki Ohara, Ken-Ichi Yamamoto, Masakiyo Sakaguchi, Teizo Yoshimura, Akihiro Matsukawa

    Gene   148874 - 148874   2024.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Hepatocellular carcinoma (HCC) remains a lethal malignancy with limited treatment options. Recent discoveries have highlighted the pivotal role of miRNAs in HCC progression. We previously reported that the expression of miR-200b-3p was decreased in HCC cells and exosomal miR-200b-3p from hepatocytes inhibited angiogenesis by suppressing the expression of the endothelial transcription factor ERG (erythroblast transformation-specific (ETS)-related gene), leading to the hypothesis that the delivery of this miRNA may inhibit angiogenesis and suppress HCC growth in vivo. Here, we tested this hypothesis by using human HCC inoculation models. First, we transfected the human HepG2 HCC cells and established a stable cell line that overexpressed a high level of miR-200b-3p. When miR-200b-3p-overexpressing cells were injected into severe combined immunedeficiency (SCID)-beige mice, tumor growth was significantly reduced compared to tumors of control cells, with a reduction in the expression of ERG and vascular endothelial growth factor (VEGF) and subsequent angiogenesis. Intra-tumoral injection of exosomes containing high levels of miR-200b-3p also reduced the growth of parental HepG2 tumors with reduced ERG and VEGF expression and angiogenesis. These results validate the inhibitory role of miR-200b-3p in tumor angiogenesis, thereby suppressing HCC tumor growth, and provide a novel insight into its potential therapeutic application.

    DOI: 10.1016/j.gene.2024.148874

    PubMed

    researchmap

  • SPRED2 Is a Novel Regulator of Autophagy in Hepatocellular Carcinoma Cells and Normal Hepatocytes. International journal

    Tianyi Wang, Tong Gao, Masayoshi Fujisawa, Toshiaki Ohara, Masakiyo Sakaguchi, Teizo Yoshimura, Akihiro Matsukawa

    International journal of molecular sciences   25 ( 11 )   2024.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Sprouty-related enabled/vasodilator-stimulated phosphoprotein homology 1 domain containing 2 (SPRED2) is an inhibitor of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway and has been shown to promote autophagy in several cancers. Here, we aimed to determine whether SPRED2 plays a role in autophagy in hepatocellular carcinoma (HCC) cells. The Cancer Genome Atlas (TCGA) Liver Cancer Database showed a negative association between the level of SPRED2 and p62, a ubiquitin-binding scaffold protein that accumulates when autophagy is inhibited. Immunohistochemically, accumulation of p62 was detected in human HCC tissues with low SPRED2 expression. Overexpression of SPRED2 in HCC cells increased the number of autophagosomes and autophagic vacuoles containing damaged mitochondria, decreased p62 levels, and increased levels of light-chain-3 (LC3)-II, an autophagy marker. In contrast, SPRED2 deficiency increased p62 levels and decreased LC3-II levels. SPRED2 expression levels were negatively correlated with translocase of outer mitochondrial membrane 20 (TOM20) expression levels, suggesting its role in mitophagy. Mechanistically, SPRED2 overexpression reduced ERK activation followed by the mechanistic or mammalian target of rapamycin complex 1 (mTORC1)-mediated signaling pathway, and SPRED2 deficiency showed the opposite pattern. Finally, hepatic autophagy was impaired in the liver of SPRED2-deficient mice with hepatic lipid droplet accumulation in response to starvation. These results indicate that SPRED2 is a critical regulator of autophagy not only in HCC cells, but also in hepatocytes, and thus the manipulation of this process may provide new insights into liver pathology.

    DOI: 10.3390/ijms25116269

    PubMed

    researchmap

▼display all

Books

  • リンパ組織

    佐藤, 康晴, 竹内, 賢吾( Role: Contributor ,  胚中心進展性異形成(PTGC))

    文光堂  2023.4  ( ISBN:9784830604911

     More details

    Total pages:viii, 283p   Language:Japanese

    CiNii Books

    researchmap

MISC

  • Pseudohypoxia by HIF-PHD inhibitors activates tumor immune response for MSS colorectal cancer.

    Toshiaki Ohara, Yuehua Chen, Yusuke Hamada, Hajime Kashima, Satoru Kikuchi, Kazuhiro Noma, Hiroshi Tazawa, Masayoshi Fujisawa, Toshiyoshi Fujiwara, Akihiro Matsukawa

    CANCER SCIENCE   116   663 - 663   2025.1

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • 癌の血管走行を深層学習した人工知能の開発

    杉山 友康, 藤澤 真義, 土井 晃一郎, 亀田 弘之, 笠井 智成, 大原 利章

    日本生物工学会大会講演要旨集   2024年   82 - 82   2024.8

     More details

    Language:Japanese   Publisher:(公社)日本生物工学会  

    researchmap

  • SPRED2の欠損はマウスの腫瘍においてオートファジーとマイトファジーを抑制する(SPRED2 deficiency downregulates autophagy and mitophagy in tumors in cancer-bearing mouse model)

    王 天一, 高 桐, 藤澤 真義, 大原 利章, 吉村 禎造, 松川 昭博

    日本病理学会会誌   113 ( 1 )   298 - 298   2024.2

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • 鉄キレート剤による抗腫瘍免疫応答の向上 マウス肺癌モデルを用いて(Iron chelator enhances the tumor immune response in lung cancer in mice)

    浜田 祐輔, 大原 利章, 王 宇沢, 陳 悦華, 藤澤 真義, 松川 昭博

    日本病理学会会誌   113 ( 1 )   370 - 370   2024.2

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • SPRED2の欠損はマウスの腫瘍においてオートファジーとマイトファジーを抑制する(SPRED2 deficiency downregulates autophagy and mitophagy in tumors in cancer-bearing mouse model)

    王 天一, 高 桐, 藤澤 真義, 大原 利章, 吉村 禎造, 松川 昭博

    日本病理学会会誌   113 ( 1 )   298 - 298   2024.2

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

▼display all

Presentations

  • 鉄キレート効果を持つHIF-PH阻害薬は抗腫瘍免疫応答を向上させる(HIF-PH inhibitors with iron chelating ability enhance the tumor immune response)

    大原 利章, 陳 悦華, 王 宇沢, 濱田 祐輔, 菊地 覚次, 野間 和広, 田澤 大, 藤澤 真義, 藤原 俊義, 松川 昭博

    日本癌学会総会記事  2023.9  (一社)日本癌学会

     More details

    Event date: 2023.9

    Language:English  

    researchmap

  • Double immunostaining for tumor vessel identification and its application in breast cancer prognosis

    Hnin Wintwint Swe, Akihiro Matsukawa, Masayoshi Fujisawa

    2022.4.16 

     More details

  • The role of Spred2 in lung adenocarcinoma

    Yoko Ota, Tong Gao, Masayoshi Fujisawa, Teizo Yoshimura, Akihiro Matsukawa

    2022.4.16 

     More details

  • Interclonal Cooperation by Exosomal Wnt7a Promotes Lung Metastasis of the 4T1 Breast Cancer cells

    Chunning Li, Teizo Yoshimura, Toshiaki Ohara, Masayoshi Fujisawa, Yuze Wang, Akihiro Matsukawa

    2022.4.16 

     More details

  • Pseudo-hypoxia by iron chelators consists anti-cancer effect and CD8+ T-cell activation

    Yuehua Chen, Toshiaki Ohara, Yuze Wang, Yusuke Hamada, Masahiro Fujisawa, Teizo Yoshimura, Akihiro Matsukawa

    2022.4.15 

     More details

▼display all

Research Projects

  • AI病理診断に向けた、組織切片の厚さの簡易計測法の開発と標準化技術の確立

    Grant number:23K11895  2023.04 - 2026.03

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    藤澤 真義, 大原 利章, 松川 昭博

      More details

    Grant amount:\4160000 ( Direct expense: \3200000 、 Indirect expense:\960000 )

    researchmap

 

Class subject in charge

  • Pathology (1) (2024academic year) special  - その他

  • Practice in Pathology (1) (2024academic year) special  - その他

  • Practicals: Pathology and Experimental Medicine (2024academic year) special  - その他

  • Research Projects: Pathology and Experimental Medicine (2024academic year) special  - その他

  • Research Projects and Practicals: Pathology and Experimental Medicine I (2024academic year) special  - その他

▼display all